Dorsa Shekouh

Dorsa Shekouh

Auto-generated profile, based on publicly available information

Dorsa Shekouh

Student Research Committee, School of Medicine Shiraz University of Medical Sciences Shiraz Iran

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2022 in Pain Practice
Verified
Journal Article
Closed access
MSMohammad Shafie’ei
Mohammad Shafie’ei
MKMohsen Farjoud Kouhanjani
Mohsen Farjoud Kouhanjani
ZAZahra Akbari
Zahra Akbari
NSNastaran Sarvipour
Nastaran Sarvipour
DSDorsa Shekouh
Dorsa Shekouh
HNHamid Nemati
Hamid Nemati

24 March 2026 in European Journal of Breast Health
Verified
Journal Article
Open access
PDF file
PMParisa Hashemi Moghanjoughi
Parisa Hashemi Moghanjoughi
SNSina Neshat
Sina Neshat
AHAfshin Heidari
Afshin Heidari
MBMatin Bidares
Matin Bidares
MMMahshid Sadat Chenarani Moghadam
Mahshid Sadat Chenarani Moghadam
RMRoya Modaresi
Roya Modaresi
Idiopathic Granulomatous Mastitis: A Comprehensive Review of Etiology, Diagnosis, and Management - European Journal of Breast Health

28 July 2026 in Health Science Reports
Verified
Journal Article
Open access
PDF file
FBFaizan Bashir
Faizan Bashir
QBQurat‐Ul‐Aine Bhat
Qurat‐Ul‐Aine Bhat
JAJayden Allegakoen
Jayden Allegakoen
DSDorsa Shekouh
Dorsa Shekouh
SZSajida Zaiter
Sajida Zaiter
Background and Aims: Circulating tumor DNA (ctDNA) has emerged as a promising biomarker of tumor burden and minimal residual disease. As total neoadjuvant therapy (TNT) increasingly supports organ‐preserving strategies in locally advanced rectal cancer (LARC), reliable markers of treatment response are needed. This review evaluates the prognostic and predictive value of ctDNA in this setting. Methods: Following PRISMA guidelines, we systematically reviewed studies across PubMed/MEDLINE, Web of Science, Cochrane and Google Scholar evaluating ctDNA during or after TNT in LARC reporting treatment‐response or survival outcomes. Results: Seven studies met inclusion criteria. Baseline ctDNA detection was near‐universal (83–100%) but lacked discriminatory value. ctDNA declined progressively during TNT, with post‐TNT negativity correlating with clinical or pathological complete response ( p = 0.007–0.038). Persistent positivity predicted residual disease and inferior survival (DFS HR 4.03; OS HR 23.0), with presurgical ctDNA in GEMCAD showing preferential association with hepatic recurrence suggesting a marker of systemic rather than locoregional disease. Post‐TNT ctDNA demonstrated high specificity but low sensitivity (23%–45%) for residual disease, and preceded clinical recurrence detection by weeks to months. Conclusions: ctDNA clearance at the end of TNT may represent a biologically meaningful marker of treatment response and recurrence risk. However, current data derive from small, heterogeneous cohorts with variable assay platforms and sampling schedules, and ctDNA's limited sensitivity precludes its use as a standalone tool for non‐operative management selection.

26 February 2026 in Journal of Ultrasound in Medicine
Verified
Journal Article
Closed access
PDF file
AAAmirmohammad Azizzadeh
Amirmohammad Azizzadeh
DSDorsa Shekouh
Dorsa Shekouh
PJParnia Jochin
Parnia Jochin
MBMohammad Babaei
Mohammad Babaei
EMEhsan Mirzaaghazadeh
Ehsan Mirzaaghazadeh
PHPeyman Kamali Hakim
Peyman Kamali Hakim

31 July 2025 in Dermatology Practical & Conceptual
Verified
Journal Article
Open access
PDF file
LDLadan Dastgheib
Ladan Dastgheib
DSDorsa Shekouh
Dorsa Shekouh
MSMozhdeh Sepaskhah
Mozhdeh Sepaskhah
ASAlireza Salehi
Alireza Salehi
Introduction: The quality of life (QoL) of patients suffering from cutaneous malignancies like cutaneous T-cell lymphoma (CTCL) and their family caregivers is widely affected by the disease and its treatment. Objectives: This study aimed to evaluate the impact of the disease and its treatment on patients with MF and their families through self-administered questionnaires in our referral center in Shiraz. Methods: Patients with MF, the most common variant of CTCL and 1 of their family members participated in this study by filling out the questionnaires on Dermatology Life Quality Index (DLQI), and Family Dermatology Life Quality Index (FDLQI). The World Health Organization Quality of Life Brief Version (WHOQOL-BREF) was also completed by patients and healthy controls. Results: A total of 113 cases, 91 patients’ relatives, and 129 healthy controls participated in this study. The mean DLQI total score was 8.00 ± 6.41. WHOQOL-BREF and/or their subdomains were ameliorated with advanced stage, active disease, increasing MSWAT score, early disease, the head/neck location, as well as interferon and gemcitabine. “Symptoms and feelings” and “leisure” dimensions of DLQI were the most affected, while regarding WHOQOL-BREF, the disease significantly impacted the “psychological”, “environmental” and “general health” aspects (P<0.001, P=0.045, and P<0.001, respectively). Given the sociodemographic characteristics of the study participants, patients with a higher level of education suffered more (P=0.035). Conclusions: Due to the distress that patients and caregivers experience during the first year of diagnosis, head/neck lesions and specific treatment, appropriate measures to prevent unrealistic expectations and better coping mechanisms are recommended.

19 August 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
PDF file
Shayan ShojaeiShayan Shojaei
Shayan Shojaei
DSDorsa Shekouh
Dorsa Shekouh
AMAsma Mousavi
Asma Mousavi
SRSalma Rostamipourfard
Salma Rostamipourfard
SKSaeed Karami
Saeed Karami
AAAlireza Arzhangzadeh
Alireza Arzhangzadeh
Background: Activation of the renin‐angiotensin‐aldosterone system contributes to hepatic inflammation in metabolic dysfunction‐associated steatotic liver disease (MASLD). Telmisartan, an angiotensin II receptor blocker with partial PPAR‐γ agonistic activity, has been hypothesized to confer metabolic benefits; however, current clinical evidence has not consistently demonstrated such effects. Aim: This systematic review and meta‐analysis evaluated the efficacy of telmisartan on metabolic, biochemical, and histological outcomes in MASLD. Methods: Electronic databases (PubMed, Embase, Web of Science, Scopus) were searched through 2026 for randomized controlled trials (RCTs) investigating telmisartan in adults with MASLD. Risk of bias was assessed using the RoB2 tool. Random‐effects meta‐analyses calculated pooled mean differences (MDs) with 95% confidence intervals (CIs). Results: Six RCTs comprising 258 participants (126 telmisartan, 132 controls) met the inclusion criteria. Telmisartan treatment was associated with a modest reduction in fasting blood sugar compared with controls (MD = −2.78 mg/dL; 95% CI −5.17 to −0.39; p = 0.023); however, this finding was accompanied by substantial heterogeneity (I 2 = 91.8%) and should therefore be interpreted cautiously. No significant changes were observed for body mass index, waist circumference, HOMA‐IR, lipid profiles, ALT, or AST. Conversely, gamma‐glutamyl transferase (GGT) levels showed a modest but significant increase with telmisartan (MD = 5.40 U/L; 95% CI 0.51 to 10.29; p = 0.031). Histological analyses revealed a non‐significant trend toward fibrosis stage improvement (MD = −0.28; 95% CI −0.57 to 0.01; p = 0.060), with no significant improvements seen in the overall NAFLD activity score, steatosis, ballooning, or lobular inflammation. Most included trials carried a low overall risk of bias. Conclusion: Current evidence does not demonstrate consistent metabolic, biochemical, or histological benefits of telmisartan in MASLD. Although a modest reduction in fasting blood glucose was observed, substantial between‐study heterogeneity and the modest effect size limit confidence in this finding.